Translational advances also depend on the use of robust biomarker panels, such as the hepcidin-to-ferritin ratio, soluble transferrin receptor levels, and BRINDA project (biomarkers reflecting inflammation and nutritional determinants of anemia)-corrected iron estimates, in metabolic disease studies. Here, HAMP is linked to metabolic disease.